RxDoctor Payments Data

Yasmine Strickland, MD

Family Medicine · Parrish, ALNPI 1134625452

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $264, more than ten times the $16 reported in 2019. That places this record below the midpoint for family medicine clinicians in AL, where the typical reported total is $638.

$732in general payments, 2019–2025

Across 37 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$136
  • Novo Nordisk$112
  • Otsuka America Pharmaceutical, Inc.$93
  • Corcept Therapeutics$81
  • Lilly USA, LLC$57
  • Merck$50
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$732 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama →

Medicare billing

Part B allowed, 2024
$11,524
Medicare patients
58
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$12,894
EliquisApixaban12$7,957
Atorvastatin Calcium82$718
Albuterol Sulfate HfaAlbuterol Sulfate36$663
Duloxetine Hcl26$659
Pregabalin11$458
Pantoprazole Sodium28$380
Rosuvastatin Calcium21$322
Metoprolol Succinate19$289
Amlodipine Besylate73$277
Methylprednisolone34$275
Fluticasone Propionate18$268
Omeprazole13$218
Losartan Potassium21$187
Potassium Chloride11$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$12,89414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Parrish

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →